Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 20, 2024 (
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
(Commission File Number) |
(I.R.S. Employer Identification No.) | |
| (Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number,
including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
At the 2024 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) held on June 14, 2024, Regeneron’s shareholders voted on the matters set forth below.
Proposal 1 – Election of Directors
The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:
| Nominee | For | Against | Abstain | Broker Non-Votes | ||||||||||||
| N. Anthony Coles, M.D. | 110,481,731 | 1,873,397 | 99,413 | 4,213,730 | ||||||||||||
| Kathryn Guarini, Ph.D. | 111,988,738 | 359,659 | 106,144 | 4,213,730 | ||||||||||||
| Arthur F. Ryan | 81,009,658 | 31,288,101 | 156,782 | 4,213,730 | ||||||||||||
| George L. Sing | 102,751,205 | 9,574,839 | 128,497 | 4,213,730 | ||||||||||||
The following nominee for Class II director was elected to serve until the 2026 Annual Meeting of Shareholders and until his successor is duly elected and qualified based upon the following votes:
| Nominee | For | Against | Abstain | Broker Non-Votes | ||||||||||||
| David P. Schenkein, M.D. | 106,839,998 | 5,501,139 | 113,404 | 4,213,730 | ||||||||||||
Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm
The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved based upon the following votes:
| For: | 111,350,016 | |||
| Against: | 5,257,636 | |||
| Abstain: | 60,619 |
Proposal 3 – Advisory Vote on Executive Compensation
The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A filed April 25, 2024 was approved based on the following votes:
| For: | 106,667,264 | |||
| Against: | 5,579,814 | |||
| Abstain: | 207,463 | |||
| Broker Non-Votes: | 4,213,730 |
Proposal 4 – Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements
The non-binding shareholder proposal requesting simple majority voting requirements was approved based upon the following votes:
| For: | 85,900,254 | |||
| Against: | 26,365,621 | |||
| Abstain: | 188,666 | |||
| Broker Non-Votes: | 4,213,730 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| REGENERON PHARMACEUTICALS, INC. | |
| /s/ Joseph J. LaRosa | |
| Joseph J. LaRosa | |
| Executive Vice President, General Counsel and Secretary |
Date: June 20, 2024